JASP_logo

“Bayesian Inference Without Tears” at CIRM

Today I am presenting a lecture for the “Masterclass in Bayesian Statistics” that takes place from October 22 to October 26th 2018, at CIRM (Centre International de Rencontres Mathématiques) in Marseille, France. The slides of my talk,“Bayesian Inference Without Tears” are here. Unfortunately the slides cannot convey the JASP demo work, but the presentations are taped so I hope to be able to provide a video link at some later point in time.

(more…)


A Bayesian Perspective on the Proposed FDA Guidelines for Adaptive Clinical Trials

The frequentist food and drug administration (FDA) has circulated a draft version of new guidelines for adaptive designs, with the explicit purpose of soliciting comments. The draft is titled “Adaptive designs for clinical trials of drugs and biologics: Guidance for industry” and you can find it here. As summarized on the FDA webpage, this draft document

 
 
 
 

“(…) addresses principles for designing, conducting and reporting the results from an adaptive clinical trial. An adaptive design is a type of clinical trial design that allows for planned modifications to one or more aspects of the design based on data collected from the study’s subjects while the trial is ongoing. The advantage of an adaptive design is the ability to use information that was not available at the start of the trial to improve efficiency. An adaptive design can provide a greater chance to detect the true effect of a product, often with a smaller sample size or in a shorter timeframe. Additionally, an adaptive design can reduce the number of patients exposed to an unnecessary risk of an ineffective investigational treatment. Patients may even be more willing to enroll in these types of trials, as they can increase the probability that subjects will be assigned to the more effective treatment.”

(more…)


Powered by WordPress | Designed by Elegant Themes